Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 78,569,000	$ 42,090,000	$ (30,302,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	711,000	544,000	479,000
Amortization on right-of-use asset	582,000	280,000	0
Stock-based compensation	7,235,000	5,767,000	1,630,000
Amortization of debt issuance costs	0	14,000	90,000
Accretion of debt discount	0	2,211,000	101,000
Change in fair value of derivatives	443,000	1,326,000	1,088,000
Change in fair value of common stock warrants liability	(21,988,000)	(30,510,000)	0
Change in fair value of preferred stock warrants liability	0	35,035,000	18,498,000
Change in fair value of earnout liability	(85,437,000)	(75,488,000)	0
Changes in operating assets and liabilities:
Other receivables	(1,734,000)	(2,563,000)	1,007,000
Grants receivable	0	0	87,000
Prepaid expenses and other current assets	432,000	(3,652,000)	53,000
Other long-term assets	(5,017,000)	0	0
Accounts payable	26,000	(395,000)	1,203,000
Accrued expenses	485,000	3,010,000	349,000
Payment on operating lease liabilities	(572,000)	(295,000)	0
Other liabilities, current	(329,000)	380,000	0
Other liabilities, long-term	502,000	203,000	256,000
Net cash used in operating activities	(26,092,000)	(22,043,000)	(5,461,000)
Cash flows from investing activities
Purchases of property, plant, and equipment, net of grants	(83,691,000)	(12,268,000)	(1,786,000)
Purchases of marketable securities	(3,823,407,000)	(2,448,316,000)	0
Sales of marketable securities	3,815,859,000	2,024,089,000	0
Maturities of marketable securities	180,331,000	25,058,000	0
Capitalized interest on plant construction	(245,000)	(201,000)	(268,000)
Net cash provided by (used in) investing activities	88,847,000	(411,638,000)	(2,054,000)
Cash flows from financing activities
Proceeds from stockholders' notes payable, net of debt issuance costs	0	11,707,000	3,166,000
Payment of short-term debt	0	(906,000)	0
Proceeds from Canadian Government Research and Development Program	849,000	543,000	2,662,000
Proceeds from exercise of stock options	399,000	74,000	1,000
Business combination, net of issuance costs paid	0	467,530,000	0
Net cash provided by financing activities	1,248,000	478,948,000	5,829,000
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies	(2,782,000)	(14,000)	(52,000)
Net increase (decrease) in cash and cash equivalents, and restricted cash	61,221,000	45,253,000	(1,738,000)
Cash and cash equivalents, and restricted cash, beginning of the period	47,127,000	1,874,000	3,612,000
Cash and cash equivalents, and restricted cash, end of the period	108,348,000	47,127,000	1,874,000
Supplemental disclosure of cash flow information
Conversion of stockholder convertible notes payable to common stock	0	20,493,000	0
Reclassification of redeemable convertible preferred stock warrants to common stock	0	54,267,000	0
Reclassification of contingently issued equity to liability	0	203,082,000	0
Net assets assumed from business combination	0	81,364,000	0
Debt discount related to derivative liability	0	2,196,000	0
Business combination transaction costs, accrued but not paid	0	609,000	0
Operating lease right-of-use assets obtained in exchange for lease obligations	1,687,000	2,062,000	0
Stock-based compensation capitalized into property, plant, and equipment	1,894,000	0	0
Purchases of fixed assets included in accounts payable and accrued expenses	$ 17,085,000	$ 0	$ 0